Mineralys Therapeutics reports Q3 EPS ($1.13), consensus (83c)

Cash, cash equivalents and investments were $263.6 M as of September 30 compared to $239M as of December 31, 2023. The Company believes that its current cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations, into 2026.”The past several months were very productive for our team, as we made significant progress advancing our pivotal clinical program for lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension,” stated Jon Congleton, Chief Executive Officer of Mineralys Therapeutics (MLYS). “We are excited that the two pivotal trials from this program are fully enrolled and on track to deliver topline data during the first half of 2025. Pending positive data from these trials, this pivotal program will be the foundation for our NDA submission to the FDA.”